# BriaCell Therapeutics Corp.: financial statements, quarterly

BCTX · Nasdaq · CIK 1610820 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jul 31

Pages: [Overview](/companies/bctx.md) · [Financials](/companies/bctx/financials.md) · [Filings](/companies/bctx/filings.md) · [Insiders](/companies/bctx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bctx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-07-31) | Q1 FY2024 (2023-10-31) | Q2 FY2024 (2024-01-31) | Q3 FY2024 (2024-04-30) | Q4 FY2024 (2024-07-31) | Q1 FY2025 (2024-10-31) | Q2 FY2025 (2025-01-31) | Q3 FY2025 (2025-04-30) | Q4 FY2025 (2025-07-31) | Q1 FY2026 (2025-10-31) | Q2 FY2026 (2026-01-31) | Q3 FY2026 (2026-04-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [5.2 d](/filings/0001493152-24-042743.md) | [6.9](/filings/0001493152-24-050214.md) | [8.3](/filings/0001493152-25-010052.md) | [7.7](/filings/0001641172-25-015265.md) | [4.4 d](/filings/0001493152-25-018212.md) | [3.7](/filings/0001493152-25-027240.md) | [5.7](/filings/0001493152-26-009557.md) | [4.8](/filings/0001493152-26-027928.md) | [7.1 d](/filings/0001493152-25-018212.md) | [6.7](/filings/0001493152-25-027240.md) | [6.1](/filings/0001493152-26-009557.md) | [6.0](/filings/0001493152-26-027928.md) |
| Operating income | $m | [(7.7) d](/filings/0001493152-24-042743.md) | [(8.5)](/filings/0001493152-24-050214.md) | [(9.8)](/filings/0001493152-25-010052.md) | [(9.2)](/filings/0001641172-25-015265.md) | [(5.8) d](/filings/0001493152-25-018212.md) | [(5.2)](/filings/0001493152-25-027240.md) | [(7.2)](/filings/0001493152-26-009557.md) | [(6.3)](/filings/0001493152-26-027928.md) | [(8.6) d](/filings/0001493152-25-018212.md) | [(8.3)](/filings/0001493152-25-027240.md) | [(7.5)](/filings/0001493152-26-009557.md) | [(7.6)](/filings/0001493152-26-027928.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001493152-26-027928.md) | [0.0 d](/filings/0001493152-25-018212.md) | not reported | not reported | [0.0](/filings/0001493152-26-027928.md) |
| Net income | $m | [(2.4) d](/filings/0001493152-24-042743.md) | [6.0](/filings/0001493152-24-050214.md) | [(11.3)](/filings/0001493152-25-010052.md) | [1.7](/filings/0001641172-25-015265.md) | [(1.2) d](/filings/0001493152-25-018212.md) | [(5.8)](/filings/0001493152-25-027240.md) | [(6.3)](/filings/0001493152-26-009557.md) | [(6.1)](/filings/0001493152-26-027928.md) | [(8.1) d](/filings/0001493152-25-018212.md) | [(8.2)](/filings/0001493152-25-027240.md) | [(7.2)](/filings/0001493152-26-009557.md) | [(7.2)](/filings/0001493152-26-027928.md) |
| Diluted EPS | $ per share | not reported | [(0.50)](/filings/0001493152-24-050214.md) | [(10.64)](/filings/0001493152-25-010052.md) | [1.61](/filings/0001641172-25-015265.md) | not reported | [(32.67)](/filings/0001493152-25-027240.md) | [(23.31)](/filings/0001493152-26-009557.md) | [(16.42)](/filings/0001493152-26-027928.md) | not reported | [(4.35)](/filings/0001493152-25-027240.md) | [(2.58)](/filings/0001493152-26-009557.md) | [(0.99)](/filings/0001493152-26-027928.md) |
| Basic EPS | $ per share | not reported | [0.38](/filings/0001493152-24-050214.md) | [(10.64)](/filings/0001493152-25-010052.md) | [1.61](/filings/0001641172-25-015265.md) | not reported | [(32.67)](/filings/0001493152-25-027240.md) | [(23.31)](/filings/0001493152-26-009557.md) | [(16.42)](/filings/0001493152-26-027928.md) | not reported | [(4.35)](/filings/0001493152-25-027240.md) | [(2.58)](/filings/0001493152-26-009557.md) | [(0.99)](/filings/0001493152-26-027928.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-07-31) | Q1 FY2024 (2023-10-31) | Q2 FY2024 (2024-01-31) | Q3 FY2024 (2024-04-30) | FY2024 (2024-07-31) | Q1 FY2025 (2024-10-31) | Q2 FY2025 (2025-01-31) | Q3 FY2025 (2025-04-30) | FY2025 (2025-07-31) | Q1 FY2026 (2025-10-31) | Q2 FY2026 (2026-01-31) | Q3 FY2026 (2026-04-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [21.3](/filings/0001493152-24-042743.md) | [13.6](/filings/0001493152-23-044892.md) | [6.2](/filings/0001493152-24-010354.md) | [0.9](/filings/0001493152-24-023867.md) | [0.9](/filings/0001493152-25-018212.md) | [5.8](/filings/0001493152-24-050214.md) | [5.0](/filings/0001493152-25-010052.md) | [12.5](/filings/0001641172-25-015265.md) | [10.5](/filings/0001493152-26-027928.md) | [2.7](/filings/0001493152-25-027240.md) | [29.9](/filings/0001493152-26-009557.md) | [6.9](/filings/0001493152-26-027928.md) |
| Current assets | $m | [26.9](/filings/0001493152-24-042743.md) | [18.4](/filings/0001493152-23-044892.md) | [11.7](/filings/0001493152-24-010354.md) | [5.5](/filings/0001493152-24-023867.md) | [3.7](/filings/0001493152-25-018212.md) | [8.2](/filings/0001493152-24-050214.md) | [7.2](/filings/0001493152-25-010052.md) | [14.8](/filings/0001641172-25-015265.md) | [19.9](/filings/0001493152-26-027928.md) | [11.3](/filings/0001493152-25-027240.md) | [32.2](/filings/0001493152-26-009557.md) | [25.4](/filings/0001493152-26-027928.md) |
| Total assets | $m | [27.2](/filings/0001493152-24-042743.md) | [18.6](/filings/0001493152-23-044892.md) | [12.2](/filings/0001493152-24-010354.md) | [6.2](/filings/0001493152-24-023867.md) | [5.9](/filings/0001493152-25-018212.md) | [10.4](/filings/0001493152-24-050214.md) | [9.4](/filings/0001493152-25-010052.md) | [17.0](/filings/0001641172-25-015265.md) | [21.6](/filings/0001493152-26-027928.md) | [13.1](/filings/0001493152-25-027240.md) | [33.6](/filings/0001493152-26-009557.md) | [27.1](/filings/0001493152-26-027928.md) |
| Current liabilities | $m | [1.8](/filings/0001493152-24-042743.md) | [1.0](/filings/0001493152-23-044892.md) | [3.9](/filings/0001493152-24-010354.md) | [6.8](/filings/0001493152-24-023867.md) | [7.5](/filings/0001493152-25-018212.md) | [5.0](/filings/0001493152-24-050214.md) | [5.2](/filings/0001493152-25-010052.md) | [4.3](/filings/0001641172-25-015265.md) | [4.0](/filings/0001493152-26-027928.md) | [3.3](/filings/0001493152-25-027240.md) | [3.2](/filings/0001493152-26-009557.md) | [3.6](/filings/0001493152-26-027928.md) |
| Shareholders' equity | $m | [(3.8)](/filings/0001493152-23-038298.md) | [2.5](/filings/0001493152-25-010052.md) | [(8.3)](/filings/0001641172-25-015265.md) | [(6.2)](/filings/0001641172-25-015265.md) | [(2.7)](/filings/0001493152-26-027928.md) | [3.7](/filings/0001493152-26-009557.md) | [3.2](/filings/0001493152-26-027928.md) | [11.9](/filings/0001493152-26-027928.md) | [17.3](/filings/0001493152-26-027928.md) | [9.4](/filings/0001493152-26-009557.md) | [30.2](/filings/0001493152-26-027928.md) | [23.4](/filings/0001493152-26-027928.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Shareholders' equity: us-gaap:StockholdersEquity, us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-07-31) | Q1 FY2024 (2023-10-31) | Q2 FY2024 (2024-01-31) | Q3 FY2024 (2024-04-30) | Q4 FY2024 (2024-07-31) | Q1 FY2025 (2024-10-31) | Q2 FY2025 (2025-01-31) | Q3 FY2025 (2025-04-30) | Q4 FY2025 (2025-07-31) | Q1 FY2026 (2025-10-31) | Q2 FY2026 (2026-01-31) | Q3 FY2026 (2026-04-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(10.9) d](/filings/0001493152-24-042743.md) | [(7.6)](/filings/0001493152-24-050214.md) | [(7.4) d](/filings/0001493152-25-010052.md) | [(5.1) d](/filings/0001641172-25-015265.md) | [(4.0) d](/filings/0001493152-25-018212.md) | [(7.0)](/filings/0001493152-25-027240.md) | [(5.9) d](/filings/0001493152-26-009557.md) | [(7.2) d](/filings/0001493152-26-027928.md) | [(8.1) d](/filings/0001493152-25-018212.md) | [(7.7)](/filings/0001493152-25-027240.md) | [(8.0) d](/filings/0001493152-26-009557.md) | [(7.0) d](/filings/0001493152-26-027928.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | Q1 FY2023 (2022-10-31) | Q2 FY2023 (2023-01-31) | Q3 FY2023 (2023-04-30) | Q1 FY2024 (2023-10-31) | Q2 FY2024 (2024-01-31) | Q3 FY2024 (2024-04-30) | Q1 FY2025 (2024-10-31) | Q2 FY2025 (2025-01-31) | Q3 FY2025 (2025-04-30) | Q1 FY2026 (2025-10-31) | Q2 FY2026 (2026-01-31) | Q3 FY2026 (2026-04-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [15.5](/filings/0001493152-23-044892.md) | [15.5](/filings/0001493152-24-010354.md) | [15.5](/filings/0001493152-24-023867.md) | [16.7](/filings/0001493152-24-050214.md) | [1.1](/filings/0001493152-25-010052.md) | [1.1](/filings/0001641172-25-015265.md) | [0.2](/filings/0001493152-25-027240.md) | [0.3](/filings/0001493152-26-009557.md) | [0.4](/filings/0001493152-26-027928.md) | [1.9](/filings/0001493152-25-027240.md) | [2.8](/filings/0001493152-26-009557.md) | [7.3](/filings/0001493152-26-027928.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 8,699,787 at 2026-06-09, from the cover of the [10-Q filed 2026-06-09](/filings/0001493152-26-027928.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.